Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Core Insights - Kymera Therapeutics is advancing KT-333, a first-in-class targeted protein degrader of STAT3, with promising Phase 1 clinical data to be presented at the European Hematology Association Annual Meeting in June 2024 [1][4] Group 1: Clinical Data and Results - The Phase 1 study of KT-333 involved 39 patients across six dose levels, with a mean of 8.7 doses administered [3] - Significant clinical responses were observed in specific patient populations, including two complete responses in classic Hodgkin's lymphoma (cHL) patients and three partial responses in cutaneous T-cell lymphoma (CTCL) patients [4] - KT-333 achieved up to 97.5% degradation of STAT3 in peripheral blood mononuclear cells, indicating effective pathway inhibition [4] Group 2: Safety and Tolerability - KT-333 was generally well-tolerated, with common adverse events including stomatitis, nausea, ALT increase, constipation, and fatigue [4] - Two dose-limiting toxicities (DLTs) were reported at the highest dose level, including Grade 3 stomatitis and arthralgia [4] Group 3: Future Development and Expectations - The ongoing Phase 1 study is expected to provide additional clinical data to inform the next development steps for KT-333 later in 2024 [3][5] - The company anticipates sharing further updates on KT-333's clinical program across various indications later this year [2]